Breaking News Instant updates and real-time market news.

KNCAY

Konica Minolta Holdings, Inc.

$0.00

(0.00%)

, ABT

Abbott

$80.54

-1.11 (-1.36%)

04:55
10/23/19
10/23
04:55
10/23/19
04:55

American College of Anesthesiologists to hold conference

Anesthesiology 2019 will be held in Orlando on October 19-23.

KNCAY

Konica Minolta Holdings, Inc.

$0.00

(0.00%)

ABT

Abbott

$80.54

-1.11 (-1.36%)

ABBV

AbbVie

$77.88

0.51 (0.66%)

ACRX

AcelRx

$2.19

(0.00%)

ATNX

Athenex

$11.54

1.95 (20.33%)

BDX

Becton Dickinson

$250.00

-4.05 (-1.59%)

EW

Edwards Lifesciences

$221.92

-5.18 (-2.28%)

EHC

Encompass Health

$67.34

0.815 (1.23%)

ETON

Eton Pharmaceuticals

$6.43

0.765 (13.52%)

THRM

Gentherm

$42.61

0.23 (0.54%)

HAE

Haemonetics

$123.29

-4 (-3.14%)

HRTX

Heron Therapeutics

$18.56

-0.465 (-2.44%)

ICUI

ICU Medical

$155.38

0.96 (0.62%)

KRO

Kronos Worldwide

$12.21

0.345 (2.91%)

MNK

Mallinckrodt

$2.86

0.32 (12.60%)

MASI

Masimo

$142.58

-2.82 (-1.94%)

MDT

Medtronic

$104.52

-2.11 (-1.98%)

MRK

Merck

$81.30

-3.24 (-3.83%)

MLSS

Milestone Scientific

$1.25

-0.05 (-3.85%)

PCRX

Pacira

$39.50

-0.15 (-0.38%)

SSNLF

Samsung

$0.00

(0.00%)

TFX

Teleflex

$322.10

-8.28 (-2.51%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 11

    Nov

  • 13

    Nov

  • 18

    Nov

  • 19

    Nov

  • 07

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

  • 17

    Mar

KNCAY Konica Minolta Holdings, Inc.
$0.00

(0.00%)

ABT Abbott
$80.54

-1.11 (-1.36%)

10/15/19
PIPR
10/15/19
NO CHANGE
PIPR
Overweight
Abbott partnership a positive for Tandem Diabetes, says Piper Jaffray
Piper Jaffray analyst JP McKim said Tandem Diabetes' (TNDM) and Abbott's (ABT) announcement that they are exploring a diabetes management closed loop system is the first step in a process that he believes will need at least 10 months, and likely more, to result in an integrated product coming to market. While he does not know if this announcement implies integration with the Libre 2.0 or Libre 3.0, his "gut is most likely Libre 3.0" but he views the news as a positive for Tandem "either way." The news will likely have a negative read-through for DexCom (DXCM), added McKim, who expects a similar announcement from Insulet (PODD) about working with Abbott as well. McKim keeps an Overweight rating and $80 price target on Tandem shares.
10/15/19
BARD
10/15/19
NO CHANGE
Target $81
BARD
Outperform
Tandem, Abbott agreement raises several questions, says Baird
Baird analyst Jeff Johnson notes that Abbott (ABT) and Tandem Diabetes (TNDM) have announced an agreement to develop and commercialize integrated diabetes solutions combining the former's next-generation FS Libre with the latter's "innovative insulin delivery systems." While the analyst is not "overly surprised" by this announcement as Tandem has long said it would eventually work with various CGM manufacturers, release timing raises several questions, including about potential for further iCGM timing delays for Libre. Regardless, Johnson sees the news as "slightly positive" for Tandem and "slightly negative" for DexCom (DXCM), but "nothing overly impactful" for either over next year or two. He has an Outperform rating and $81 price target on Tandem's shares.
10/15/19
OPCO
10/15/19
NO CHANGE
OPCO
Outperform
DexCom should be bought after 'negative' Tandem headline, says Oppenheimer
Oppenheimer analyst Steven Lichtman said Tandem Diabetes' (TNDM) announcement that it is exploring integrated solutions with Abbott (ABT) is a potential long-term positive as integration with the latter's Libre system would expand the former's reach with patients. While a "negative headline" for DexCom (DXCM), he would be a buyer on weakness, arguing that it is still early in the process and DexCom "continues to march forward toward" G-7, with a limited launch of the CGM expected in late 2020. Lichtman has Outperform ratings on both Tandem and DexCom.
10/17/19
LSCM
10/17/19
NO CHANGE
Target $100
LSCM
Buy
Tandem Diabetes partnership offers 'substantial opportunity,' says Lake Street
Lake Street analyst Brooks O'Neil believes Tandem Diabetes' (TNDM) partnership with Abbott (ABT) offers the company "substantial opportunity." Abbott's Libre opens a "huge incremental opportunity" for Tandem both in the U.S. and around the world, O'Neil tells investors in a research note. In addition, the deal likely opens the "door wide" for further positive reimbursement decisions for Tandem, contends the analyst. He keeps a Buy rating on Tandem Diabetes with a $100 price target.
ABBV AbbVie
$77.88

0.51 (0.66%)

10/10/19
STFL
10/10/19
NO CHANGE
Target $135
STFL
Buy
Reata Pharmaceuticals 'bold move' should be well received by Street, says Stifel
Stifel analyst Adam Walsh notes that in "a bold move" likely to be well received by the Street, Reata Pharmaceuticals (RETA) reacquired ex-U.S. rights to BARD, OMAV, and other Nrf2 activators from AbbVie (ABBV) for total deal consideration of $330M. Given AbbVie's lack of a significant renal franchise, the reacquisition of ex-U.S. BARD rights restores strategic flexibility to Reata and provides the opportunity to either find a more engaging development partner, go it alone ex-U.S., or sell the company outright, he contends. Further, the analyst believes the deal terms look "highly reasonable" relative to potential ex-U.S. BARD sales. Walsh has a Buy rating and $135 price target on Reata's shares.
09/26/19
SBSH
09/26/19
UPGRADE
SBSH
Buy
AbbVie upgraded to Buy from Neutral at Citi
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral.
09/26/19
SBSH
09/26/19
UPGRADE
Target $90
SBSH
Buy
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential of both Skyrizi and Rinvoq.
09/26/19
09/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Outperform from Market Perform at Wells Fargo analyst Timothy Willi saying the company's fundamentals remain strong while investor sentiment is "overly negative and close to inflecting." 2. Whirlpool (WHR) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Rehaut saying he expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at BMO Capital with analyst Amit Sharma saying Truly is "primed to capture" strong consumer demand and higher distribution/shelf space for hard seltzer. 4. AbbVie (ABBV) upgraded to Buy from Neutral at Citi with analyst Andrew Baum saying he believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." 5. Hologic (HOLX) upgraded to Buy from Neutral at BofA/Merrill with analyst Ivy Ma saying she sees the company being on "steadier footing with organic growth upside in FY20" thanks to its tuck-in acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACRX AcelRx
$2.19

(0.00%)

02/15/19
02/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cubic (CUB) initiated with a Buy at Citi. 2. Del Frisco's (DFRG) initiated with a Neutral at JPMorgan. 3. Lindblad Expeditions (LIND) initiated with a Buy at Stifel. 4. CareDx (CDNA) initiated with a Buy at Jefferies. 5. AcelRx (ACRX) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/05/19
FBCO
08/05/19
INITIATION
Target $7
FBCO
Outperform
AcelRx assumed with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman assumed coverage of AcelRx with an Outperform rating and $7 price target.
04/24/19
RILY
04/24/19
INITIATION
Target $6.5
RILY
Buy
AcelRx resumed with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva resumed coverage of AcelRx Pharmaceuticals with a Buy rating and $6.50 price target. The firm had a Buy rating and $7.50 price target on the shares under previous analyst Craig Ellis.
07/10/19
FBCO
07/10/19
INITIATION
Target $7
FBCO
Outperform
AcelRx assumed with an Outperform at Credit Suisse
Credit Suisse analyst Uy Ear assumed coverage of AcelRx with an Outperform rating and $7 price target.
ATNX Athenex
$11.54

1.95 (20.33%)

03/29/19
RHCO
03/29/19
INITIATION
Target $20
RHCO
Buy
Athenex initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated Athenex with a Buy and $20 price target, saying he is positive on the company's "hydra-like" approach to killing cancer with T-cell, Kinases, and improved chemo therapies. Among the catalysts, the analyst notes that Athenex should have two New Drug Applications by the second half of 2020 with a sales force already in place and also points to its mid-2019 Phase 3 data for oral-chemo candidate Oraxol that "looks de-risked based on Phase 2 data." Lawson also believes that risk-reward on Athenex is positive for the next 12 months with shares trading below IPO levels.
07/30/19
RHCO
07/30/19
NO CHANGE
Target $30
RHCO
Buy
Athenex price target raised to $30 from $20 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Athenex to $30 and kept his Buy rating. The analyst is rolling the company's existing pharmaceutical division product revenues into his valuation model while also assigning an 80% likelihood of success ahead of its upcoming Oraxol data.
08/07/19
RHCO
08/07/19
NO CHANGE
Target $30
RHCO
Buy
Athenex's paclitaxel phase 3 data 'positive' for NDA and pipeline, says SunTrust
SunTrust analyst Peter Lawson is keeping his Buy rating and $30 price target on Athenex after the company announced that its Oral paclitaxel and encequidar met primary endpoint in a Phase 3 study with a "very encouraging" readout relative to IV paclitaxel. The analyst notes that the overall response rate of 36% in the Oral version exceeded the 24% for IV and came in better than "over 30%" that he expected. Lawson adds that the "encouraging" topline data should support a New Drug Application filing and the development of other oral chemo programs.
08/07/19
RBCM
08/07/19
NO CHANGE
Target $31
RBCM
Outperform
Athenex's Oraxol data 'near best-case,' says RBC Capital
Athenex announced results from the phase 3 trial of Oraxol in metastatic breast cancer patients that "approach a best case scenario," according to RBC Capital analyst Kennen MacKay, who views these data as demonstrating outstanding efficacy, durability, and safety/tolerability improvement. He models Oraxol achieving peak risk-unadjusted U.S. sales of $1B and global sales of $1.5B in metastatic breast cancer, noted MacKay, who expects the stock to trade to roughly $30 per share following the data. He keeps an Outperform rating and $31 price target on Athenex shares.
BDX Becton Dickinson
$250.00

-4.05 (-1.59%)

05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/19
ARGS
06/21/19
NO CHANGE
Target $290
ARGS
Buy
FDA advisory committee review of Becton Dickinson's DCB's a positive, says Argus
Argus analyst David Toung kept his Buy rating and $290 price target on Becton Dickinson, saying the recommendation by the FDA advisory committee that the company performs additional evaluation of the long-term safety of its drug-coated balloons, or DCBs, is a "positive" for the stock. The analyst states that the committee "notably" highlighted the benefit of the balloons and did not recommend that the product is removed from the market. Toung adds that as Becton Dickinson progresses with its acquisition of C.R. Bard, it is "delivering" on revenue growth, margin expansion, and revenue synergies, even though the regulatory advisory from the FDA has lowered his assumed FY19 and FY20 EPS view by 45c and 25c to $11.75 and $13.15 respectively.
08/06/19
PIPR
08/06/19
NO CHANGE
PIPR
Becton Dickinson price target lowered to $266 from $267 at Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating on Becton Dickinson, but lowered his price target on shares to $266 from $267, following the company's Q3 earnings results. Quirk said the quarter, which beat on EPS and missed slightly on revenue, with management reiterating FY19 guidance, was "good, not great." The analyst also noted that Becton Dickinson is accelerating the growth curve in the second half of the year, which he called a "positive indicator."
09/26/19
WELS
09/26/19
NO CHANGE
WELS
Outperform
Becton Dickinson CEO transition not surprising, timing makes sense, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Becton Dickinson announced that current chairman and CEO Vince Forlenza will retire as CEO on January 1st, 2020 and that Tom Polen, current president and COO, will step into the role CEO and President. The analyst says the news does not come as a surprise based on management commentary over the past year, his tenure at Becton Dickinson and his age. The timing of the transition makes sense as the company enters the last year of BCR integration and is looking at the next phase of growth in 2021 and beyond, he contends. Overall, Biegelsen does not expect any material changes to Becton Dickinson's outlook or strategic direction under Polen's leadership. The analyst has an Outperform rating on the shares.
EW Edwards Lifesciences
$221.92

-5.18 (-2.28%)

09/23/19
PIPR
09/23/19
INITIATION
Target $240
PIPR
Overweight
Edwards Lifesciences initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Adam Maeder started Edwards Lifesciences with an Overweight rating and $240 price target. While the company trades at "multiple turns" above its large-cap peers, the stock can continue to work at current levels, Maeder tells investors in a research note. The analyst believes there is still upside to the "already high" Street expectations in the second half of 2019 and 2020. U.S. low-risk approval should give the broader transcatheter aortic valve replacement market "a shot in the arm," says Maeder.
07/24/19
RAJA
07/24/19
NO CHANGE
Target $232
RAJA
Outperform
Edwards Lifesciences price target raised to $232 from $200 at Raymond James
Raymond James analyst Jayson Bedford raised his price target for Edwards Lifesciences to $232 from $200 on increased confidence given a sharp acceleration in TAVR growth and an earlier than expected approval for Low Risk. The analyst reiterates an Outperform rating on the shares.
10/14/19
FBCO
10/14/19
NO CHANGE
Target $261
FBCO
Outperform
Edwards Lifesciences price target raised to $261 from $226 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Edwards Lifesciences to $261 from $226 as rising confidence in U.S. TAVR market drives stock and expectations higher. The analyst notes that the stock has "significantly" outperformed his universe over the past few months and year to date, driven by superiority of Low-Risk TAVR clinical trial results in March, and "very strong" performance of the company's U.S. TAVR business in Q2. Feedback on this market from clinicians remains positive, and Street estimates have creeped higher in recent weeks as a result, he adds. Miksic reiterates an Outperform rating on the shares.
10/22/19
RBCM
10/22/19
NO CHANGE
Target $250
RBCM
Outperform
Edwards Lifesciences price target raised to $250 from $217 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Edwards Lifesciences to $250 and kept his Outperform rating going into its Q3 results. The analyst notes that the consensus forecast for U.S. transcatheter aortic valve replacement, or TAVR, is high with estimated growth rate in high teens, though the buy-side is estimating that rate to be over 20%. Henry adds that the company stands to benefit from the August FDA approval of SAPIEN 3 for low-risk patients and from its "landmark" Partner 3 results.
EHC Encompass Health
$67.34

0.815 (1.23%)

09/16/19
DBAB
09/16/19
INITIATION
Target $70
DBAB
Hold
Encompass Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Justin Bowers started Encompass Health with a Hold rating and a $70 price target as part of his broader research note into the Post-Acute sector in the Healthcare Facilities industry, saying the fundamentals of the public home health pure-plays are attractive despite payment reform beginning in 2020. The analyst is also positive on the company's "high quality management team" and its "market leading franchises", but sees its 2020 headwind in the home health and hospice segment as too "brisk" to overcome, stating that its high mix of therapy will pressure the segment next year.
09/16/19
DBAB
09/16/19
INITIATION
DBAB
Hold
Encompass Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Justin Bowers startedEncompass Health with a Hold rating and $70 price target.
10/21/19
SPHN
10/21/19
INITIATION
Target $77
SPHN
Overweight
Encompass Health resumed with an Overweight at Stephens
Stephens analyst Scott Fidel resumed coverage of Encompass Health with an Overweight rating and $77 price target. He sees solid growth potential from the company's joint venture strategy with acute care hospitals, Fidel stated.
09/06/19
BOFA
09/06/19
UPGRADE
Target $73
BOFA
Buy
Encompass Health upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Kevin Fischbeck upgraded Encompass Health to Buy from Neutral with a $73 price target. While 2020 will be a reset year, Encompass has already taken down expectations to the point where the risks appear priced in, Fischbeck tells investors in a research note. He believes the company is well positioned to adjust to home health reimbursement changes and points out it has little exposure to "Medicare for All" headline risk.
ETON Eton Pharmaceuticals
$6.43

0.765 (13.52%)

09/20/19
09/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Roku (ROKU) initiated with a Sell at Pivotal Research. 2. Carvana (CVNA) initiated with an Outperform at Oppenheimer. 3. Zealand Pharma (ZEAL) and MyoKardia (MYOK) were initiated with a Buy at Guggenheim. 4. Wayfair (W) initiated with a Sell at Berenberg. 5. Eton Pharmaceuticals (ETON) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/19
RILY
09/20/19
INITIATION
Target $13.5
RILY
Buy
B. Riley FBR starts Eton Pharmaceuticals with Buy rating, $13.50 target
B. Riley FBR analyst Andrew D'Silva initiated coverage of Eton Pharmaceuticals with a Buy rating and $13.50 price target. The company is progressing toward several key commercialization milestones tied to various candidates in its pipeline, D'Silva tells investors in a research note. He points out that s. ET-202, for the treatment of hypotension during epidural and spinal anesthesia, and ET-105, an oral liquid formulation of lamotrigine for epilepsy treatment, have FDA action dates scheduled for October 2019 and March 2020, respectively. The analyst sees near-term catalysts for the shares.
09/20/19
RILY
09/20/19
INITIATION
Target $13.5
RILY
Buy
Eton Pharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR started Eton Pharmaceuticals with a Buy rating and $13.50 price target.
08/05/19
LSCM
08/05/19
INITIATION
Target $15
LSCM
Buy
Eton Pharmaceuticals initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil started Eton Pharmaceuticals with a Buy rating and $15 price target. The company has a "diversified" pipeline of 12 product candidates in various stages of development which are targeting a number of therapeutic areas, O'Neil tells investors in a research note. The analyst sees the potential for $69M of revenue from the first three of the 12 products in its pipeline. Further, he believes Eton's management team has a track record of successfully growing businesses through "value-creating business development activities."
THRM Gentherm
$42.61

0.23 (0.54%)

07/29/19
ARGS
07/29/19
DOWNGRADE
ARGS
Hold
Gentherm downgraded to Hold from Buy at Argus
02/21/19
CHLM
02/21/19
DOWNGRADE
CHLM
Hold
Gentherm downgraded to Hold from Buy at Craig-Hallum
02/21/19
CHLM
02/21/19
DOWNGRADE
Target $46
CHLM
Hold
Craig-Hallum downgrades Gentherm to Hold, calls 2021 targets 'aggressive'
As previously reported, Craig-Hallum analyst Steve Dyer downgraded Gentherm to Hold from Buy, stating that he thinks the company's 2021 targets look "increasingly optimistic" and "aggressive" given the more challenging auto market. Though he views Gentherm as "a unique story," Dyer thinks multiple expansion and further valuation deviation from the secular growth auto supplier group is unlikely in the near term, he tells investors. He lowered his FY19 estimates to reflect the continued challenging automotive industry and cut his price target on Gentherm shares to $46 from $48.
07/29/19
ARGS
07/29/19
DOWNGRADE
ARGS
Hold
Gentherm downgraded to Hold from Buy at Argus
Argus analyst David Coleman downgraded Gentherm to Hold after its recent "disappointing" Q2 results and a cut in its FY19 sales outlook driven by the "challenging" macro and auto industry environment. The analyst believes that the current 21.4-times expected FY19 earnings multiple - near the midpoint of its 11.7-33.0-times historical average and above the median peers' 15.2-times - is a "fair valuation" for Gentherm.
HAE Haemonetics
$123.29

-4 (-3.14%)

08/07/19
JMPS
08/07/19
NO CHANGE
Target $145
JMPS
Outperform
Haemonetics price target raised to $145 from $128 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Haemonetics to $145 and kept his Outperform rating after its "strong" above-consensus Q2 results. The analyst believes that the company can generate "impressive" earnings growth over the coming years thanks to the volumes and pricing benefits coming from its Plasma division, as well as through margin expansion, share buybacks, and additional cost-saving initiatives.
08/07/19
JEFF
08/07/19
NO CHANGE
Target $165
JEFF
Buy
Haemonetics price target raised to $165 from $140 at Jefferies
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $165 from $140 saying the company's fiscal Q1 results reinforced his core thesis. The company offers "significant" earnings upside potential in the years ahead on a combo of Plasma volumes, NexSys benefits, and cost savings, Petrone tells investors in a research note. He believes "things trending in the right direction" for Haemonetics and keeps a Buy rating on the shares. The analyst's upside case is now $200 per share, up from $175.
08/07/19
BRRR
08/07/19
NO CHANGE
Target $139
BRRR
Outperform
Haemonetics price target raised to $139 from $116 at Barrington
Barrington analyst Michael Petusky raised his price target for Haemonetics to $139 from $116 citing the company's "strong" fiscal Q1 results. Strong gross margin was the primary driver of the "exceptionally positive" profitability surprise, Petusky tells investors in a research note. He maintains an Outperform rating on Haemonetics.
08/02/19
JEFF
08/02/19
NO CHANGE
Target $140
JEFF
Buy
Haemonetics price target raised to $140 from $125 at Jefferies
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $140 from $125 to reflect the company's new reporting structure. The target reflects optically higher growth in Plasma as the customer-centric reporting structure better captures underlying trends in disposables, Petrone tells investors in a research note. Beyond optics, the analyst sees worsening IVIG drug shortages as supportive of upside to Haemonetics' Plasma growth. He keeps a Buy rating on the shares.
HRTX Heron Therapeutics
$18.56

-0.465 (-2.44%)

06/28/19
COWN
06/28/19
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics issues resolvable, shares undervalued, says Cowen
Cowen analyst Boris Peaker reviewed inspection reports of manufacturing facilities contracted by Heron Therapeutics. The analyst said based on the contents, he believes the issues are resolvable. The analyst also continues to anticipate NDA submission for HTX-011 in the second half of the year and believes the shares are undervalued. Peaker reiterated his Outperform rating and $40 price target on Heron Therapeutics shares.
08/06/19
JEFF
08/06/19
NO CHANGE
Target $37
JEFF
Buy
Heron Therapeutics shares could hit low $20s on re-filing, says Jefferies
Heron Therapeutics is trading near its 52-week low and the timeline for resolution of HTX-011's Complete Response Letter remains the key focus for investors, Jefferies analyst Biren Amin tells investors in a research note. By the analyst's estimate, a re-filing could happen in late September or early October, tracking towards a Q2 of 2020 launch. Heron shares could be back to the low $20s with a near-term re-filing announcement, says Amin. He keeps a Buy rating on the name with a $37 price target.
10/03/19
JMPS
10/03/19
NO CHANGE
Target $32
JMPS
Outperform
Heron Therapeutics price target lowered to $32 from $38 at JMP Securities
JMP Securities analyst Liisa Bayko lowered her price target on Heron Therapeutics to $32 but kept her Outperform rating after its topline Phase 3b results for HTX-011 indicating that 75% of patients did not require opioids to manage their postoperative pain through 72 hours. The analyst notes that based on the FDA guidance to this point, she does not expect the agency to grant HTX-011 an "opioid sparing label", but she sees the "positive" results of the study supporting the company's case with the agency ahead of its PDUFA date in March.
10/01/19
JMPS
10/01/19
NO CHANGE
Target $38
JMPS
Outperform
Heron Therapeutics price target increased to $38 from $33 at JMP Securities
JMP Securities analyst Joseph Osha maintained a Market Outperform rating on Heron Therapeutics and raised his price target on the shares to $38 from $33 after the company resubmitted its New Drug Application to the FDA for HTX-011, an investigational agent for the management of postoperative pain. Osha said he is "pleased" with management's timely resolution of the complete response letter issues concerning additional chemistry, manufacturing and controls as well as non-clinical information. The analyst added that he now anticipates a launch roughly 6-8 weeks following the late March PDUFA date.
ICUI ICU Medical
$155.38

0.96 (0.62%)

08/08/19
RAJA
08/08/19
DOWNGRADE
Target $205
RAJA
Outperform
ICU Medical downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Jayson Bedford downgraded ICU Medical to Outperform from Strong Buy and lowered his price target to $205 from $295. In a research note to investors, Bedford says that the company's earnings revision, while amplified by transient costs, is too big to ignore and the profitability of the business has been impaired, which impacts the ultimate value of the company. The analyst adds that he still believes ICU has a rightful place in the infusion therapy market and feels that, at some point, its share should improve, and while acknowledging that this setback is a hit to credibility, he still believes this management team can create value
08/08/19
RAJA
08/08/19
DOWNGRADE
RAJA
Outperform
ICU Medical downgraded to Outperform from Strong Buy at Raymond James
KRO Kronos Worldwide
$12.21

0.345 (2.91%)

10/11/19
RHCO
10/11/19
NO CHANGE
Target $108
RHCO
Hold
SunTrust sees 'lackluster' September quarter results from chemical companies
SunTrust analyst James Sheehan tells investors in a research note that he expects chemical companies to report in-line to below-consensus Q3 results driven by the trade war, slowing GDP in Europe, weak automotive and manufacturing end markets, loosening supply/demand for certain commodity product chains and FX headwinds. Looking ahead, the analyst sees "cautious" commentary for Q4 given the lack of end market acceleration and continued USD strength. The analyst lowered his price target for Chemours (CC) to $16 from $14, for Dow Inc (DOW) to $46 from $52, for Corteva (CTVA) to $28 from $30, for DuPont (DD) to $68 from $75, for Eastman Chemical (EMN) to $75 from $80, for Element Solutions (ESI) to $10 from $11, for Kraton (KRA) to $24 from $33 and for Kronos Worldwide (KRO) to $12 from $13. Sheehan raised his price target for Celanese (CE) to $120 from $108.
11/23/18
DBAB
11/23/18
NO CHANGE
Target $15
DBAB
Buy
Deutsche cuts Kronos target to $15 but sees attractive valuation here
Deutsche Bank analyst David Begleiter lowered his price target for Kronos Worldwide to $15 from $26 but keeps a Buy rating on the shares. After declining 50%, the stock fully reflects falling European TiO2 prices and broader concerns over the TiO2 cycle, Begleiter tells investors in a research note. European TiO2 prices fell 4% in Q4 and are likely to fall further in Q1 amid soft demand, destocking and increased Chinese exports, says the analyst. However, Begleiter continues to believe industry fundamentals are supportive of an elongated TiO2 cycle. He views Kronos Worldwide's valuation as attractive at current share levels.
MNK Mallinckrodt
$2.86

0.32 (12.60%)

09/10/19
STFL
09/10/19
NO CHANGE
STFL
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $8 price target on Mallinckrodt, but noted that Mallinckrodt announced the sale of its CDMO organization, BioVectra, to HIG Capital for a potential $250M, which the analyst believes is "a positive step to manage and bolster cash and maintain capital allocation priorities." Samimy added that, with the departure of Specialty Generics President Matthew Harbaugh, the company's suspension of the spin-off appears indefinite.
09/05/19
09/05/19
DOWNGRADE
Target $3

Market Perform
Mallinckrodt cut to Market Perform at BMO Capital on opioid restructuring report
As previously reported, BMO Capital analyst Gary Nachman downgraded Mallinckrodt to Market Perform and slashed his price target to $3 from $19 after yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. The analyst contends that an already challenging situation has "taken a turn for the worse", stating that he previously believed that the company would be able to navigate through these issues. Nachman adds that with the mounting pressures related to the litigation, the possibility of bankruptcy for Mallinckrodt can no longer be ruled out.
09/05/19
09/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Group (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at BMO Capital analyst Gary Nachman citing yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. 3. Yirendai (YRD) downgraded to Underperform from Neutral at Macquarie with analyst Dexter Hsu saying the company not only reported "disappointing" Q2 results, but also closed the merger with CreditEase on unfavorable terms. 4. Green Dot (GDOT) downgraded to Hold from Buy at Jefferies with analyst John Hecht saying the company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors. 5. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the downgrade reflects its peer leading exposure to international gas prices which are forecasted lower through 2020 and as a result could limit its free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/19
STFL
09/09/19
NO CHANGE
Target $8
STFL
Hold
Mallinckrodt price target lowered to $8 from $20 at Stifel
Stifel analyst Annabel Samimy lowered her price target for Mallinckrodt shares to $8 from $20 after she reduced her expected growth of Acthar for 2019 and beyond and factored in more concrete potential litigation cash-calls. She models a $300M potential settlement with CMS related to the Acthar AMP-pricing reversion and has included a $900M potential liability for opioid-litigation payments, calling those her "best, reasonable estimates at this point" but acknowledging there still remains considerable uncertainty around both issues. Mallinckrodt's settlement of Track 1 of the Ohio multi-district litigations is "only a small step in the sprawling opioid litigation," but the settlement buys the company much-needed time to address New York state litigation or a global settlement, said Samimy, who keeps a Hold rating on Mallinckrodt shares.
MASI Masimo
$142.58

-2.82 (-1.94%)

05/07/19
PIPR
05/07/19
NO CHANGE
Target $148
PIPR
Overweight
Masimo price target raised to $148 from $140 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Masimo to $148 from $140 following the company's better than expected Q1 results and increased outlook. The analyst now has higher confidence in the company's prospects heading into the analyst day and he reiterates an Overweight rating on the shares.
05/17/19
STFL
05/17/19
NO CHANGE
Target $160
STFL
Buy
Masimo price target raised to $160 from $150 at Stifel
Stifel analyst Rick Wise raised his price target on Masimo shares to $160 from $150 following the company's analyst day meeting, stating that the event reinforced his view of Masimo as a consistent high-single-to low-double digit top-line grower "with an equally impressive margin expansion opportunity." He also left the event with an even greater appreciation for the depth and breadth of Masimo's suite of solutions and its pipeline, said Wise, who keeps a Buy rating on the stock.
05/17/19
PIPR
05/17/19
NO CHANGE
Target $160
PIPR
Overweight
Masimo price target raised to $160 from $148 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Masimo to $160 from $148 citing greater visibility into the company's pipeline opportunities following its analyst day. Masimo is widening its technology advantage over competitors, and also opening "several attractive" multi-billion dollar markets, Quirk tells investors in a research note. Masimo introduced Opioid SafetyNet, a home monitoring too, as well as a noninvasive PaO2 and malaria test, the analyst points out. He believes Masimo shares can continue working higher.
04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Masimo downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Masimo (MASI) to Neutral mainly on valuation concerns, stating that while nothing has changed in his positive expectations for the company's performance, the stock may be "running out of steam". The analyst believes that Masimo should continue "taking market share, post strong revenue growth supported by multiple drivers, and enjoy adoption uplift through the Philips (PHG) co-marketing deal", but also sees the valuation on the stock reflecting "a good deal of the good news".
MDT Medtronic
$104.52

-2.11 (-1.98%)

09/25/19
GUGG
09/25/19
NO CHANGE
GUGG
Neutral
Medtronic financial projections for Hugo robot 'underwhelming,' says Guggenheim
After attending Medtronic's (MDT) "much-anticipated" robotic-assisted surgery event, where the company gave a first look at the Hugo RAS system, Guggenheim analyst Chris Pasquale noted that the company gave an update on regulatory timelines and initial revenue targets, though information on pricing and clinical comparability to Intuitive Surgical's (ISRG) da Vinci system were "notably absent." He was impressed by certain design elements, though he thinks management's financial projections for Hugo were "somewhat underwhelming," said Pasquale, who keeps a Neutral rating on Medtronic shares.
09/16/19
JPMS
09/16/19
NO CHANGE
JPMS
Overweight
Medtronic one of the few that could see multiple expansion, says JPMorgan
JPMorgan analyst Robbie Marcus believes Medtronic's pipeline is "deep and often overlooked." He sees a number of "significant potential catalysts" over the coming year that he believes many investors aren't focused on. The analyst thinks investors will want to own Medtronic not only for the expected sales acceleration, from ~4% this fiscal year to ~5% in fiscal 2021, but also for the potential upside in the out-years as pipeline catalysts, that "aren't appropriately modeled by the Street," play out. Medtronic is one of the few large-cap names that could see further multiple expansion, says Marcus, who reiterates an Overweight rating on the shares.
09/27/19
PIPR
09/27/19
NO CHANGE
PIPR
Piper says insulin pump survey most positive for Insulet
Piper Jaffray analyst JP McKim conducted an insulin delivery survey in August and found that pump penetration is going "much higher" both in type 1s and in type 2s. The growth in the type 2 market is underappreciated by investors and will largely benefit Insulet (PODD) today given the pharmacy channel increases that access, McKim tells investors in a research note. Further, survey indicated that Medtronic (MDT) is expected to lose between 1,100-1,300 basis points of market share with Tandem Diabetes (TNDM) being the greatest beneficiary with the biggest uptick forecast in 2020, says the analyst. McKim views the insulin pump survey as most positive for Insulet.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $633
PIPR
Overweight
Piper says Intuitive Surgical overhang over after Medtronic unveils Hugo
Medtronic (MDT) yesterday afternoon showcased its long-awaited multi-port surgical robot Hugo, which will compete with Intuitive Surgical's (ISRG) da Vinci, Piper Jaffray analyst Matt O'Brien tells investors in a research note. As expected, Medtronic's robot is a fully modular system with an open console design and 3D vision, says the analyst. He believes Hugo should garner interest from hospitals considering its value proposition. However, Medtronic's system is at least two years out from the U.S., and the company will not be giving the system away for free like some feared, explains O'Brien. Competition has been an overhang for Intuitive for the last several months, says O'Brien, who left yesterday "feeling A LOT better about Intuitive's competitive positioning and long term growth potential." He believes Intuitive Surgical's overhang is over and that the company is likely to remain the market leader. The analyst keeps an Overweight rating on the shares with a $633 price target. O'Brien also has an Overweight rating on Medtronic with a $120 price target.
MRK Merck
$81.30

-3.24 (-3.83%)

10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.
10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
10/16/19
BOFA
10/16/19
INITIATION
Target $90
BOFA
Neutral
Merck reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Merck with a Neutral rating and $90 price target. The analyst said he has a conservative near-term outlook on Merck as he sees "limited higher-impact events driving further positive sentiment."
10/10/19
JPMS
10/10/19
NO CHANGE
Target $96
JPMS
Overweight
JPMorgan analysis indicates 'highly inexpensive valuation' for Merck
Investor sentiment on Merck shares remains positive but relative valuation and Keytruda concentration remains the primary pushback on the thesis, JPMorgan analyst Chris Schott tells investors in a research note. However, the analyst's sum-of-the-parts valuation analysis indicates a "highly inexpensive valuation" when incorporating a premium for the company's Animal health and Vaccines franchises. Further, while Keytruda represents a sizable portion of Merck's earnings and growth, the company has a full decade to further develop its pipeline and next-generation product offerings before the product faces biosimilar competition, Schott contends. As such, he continues to see Merck as one of the best positioned names in his coverage group. The analyst keeps an Overweight rating on the shares with a $96 price target.
MLSS Milestone Scientific
$1.25

-0.05 (-3.85%)

PCRX Pacira
$39.50

-0.15 (-0.38%)

06/11/19
LEHM
06/11/19
INITIATION
Target $52
LEHM
Overweight
Pacira initiated with an Overweight at Barclays
Barclays analyst Balaji Prasad started Pacira BioSciences with an Overweight rating and $52 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
05/30/19
JEFF
05/30/19
NO CHANGE
Target $37
JEFF
Buy
Heron Therapeutics target raised to $37 after doctor survey at Jefferies
Jefferies analyst Biren Amin raised his price target for Heron Therapeutics (HRTX) to $37 from $35 after conducting an expert survey prior to the company's FDA action date. The analyst's survey of 50 U.S. doctors suggests HTX-011 would capture the majority of its share from generic bupivacaine, with the remainder from Pacira's (PCRX) Exparel. Importantly, doctors view the opioid-sparing effect of TX-011 as compelling, Amin tells investors in a research note. HE keeps a Buy rating on the shares.
05/02/19
STFL
05/02/19
UPGRADE
Target $45
STFL
Hold
Stifel upgrades Pacira to Hold after Heron competition delayed
As previously reported, Stifel analyst Derek Archila upgraded Pacira (PCRX) to Hold from Sell after Heron Therapeutics (HRTX) announced yesterday that it received a Complete Response Letter from the FDA for its New Drug Application for HTX-011 for the management of postoperative pain. Archila now forecasts HTX-011's approval and launch in 2020 and thinks Pacira's Exparel will likely remain the only local, non-opioid, long-acting analgesic on the market through the remainder of 2019. He also believes a recent price increase and a favorable reimbursement scheme in the ASC setting should set the company up to achieve its 2019 Exparel guidance. However, Archila said key points from his Sell thesis still worry him long-term as he thinks other more competitive offerings, from Heron and others, will eventually come to market. Given his increased Exparel forecast and the incorporation of the recent acquisition of Iovera, Archila raised his price target on Pacira shares to $45 from $33.
05/06/19
MZHO
05/06/19
UPGRADE
Target $38
MZHO
Neutral
Pacira upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Pacira Biosciences (PCRX) to Neutral from Underperform and raised her price target for the shares to $38 from $29. The analyst says her sell thesis on the shares is longer valid due to an unexpected delay at competitor Heron Therapeutics (HRTX) and Pacira's stronger guidance on recently acquired iovera. However, she still remains concerned about the longer-term outlook for the company.
SSNLF Samsung
$0.00

(0.00%)

08/08/19
08/08/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Apple (AAPL), Samsung (SSNLF), HP Enterprise (HPE), HP Inc. (HPQ), and Dell Technologies (DELL) initiated with an Equal Weight at Barclays. 2. Avalara (AVLR) initiated with an Outperform at William Blair. 3. BlueLinx (BXC) initiated with a Buy at B. Riley FBR. 4. Corning (GLW) initiated with an Overweight at Barclays while Seagate (STX) was initiated with an Underweight, and Western Digital (WDC) was initiated with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/16/19
RBCM
07/16/19
NO CHANGE
RBCM
Outperform
Micron may gain from Japan-Korea trade spat, says RBC Capital
RBC Capital analyst Mitch Steves keeps his Outperform rating on Micron (MU) and notes that the company may be a "second derivative" beneficiary from the trade tensions between Japan and South Korea. The analyst contends that if SK Hynix and Samsung (SSNLF) are "forced" to procure high-purity hydrogen fluoride from a new source, Micron may gain market share as customers in the "mission-critical" data center environment shift their spending.
10/22/19
BERN
10/22/19
NO CHANGE
BERN
Outperform
Bernstein sees signs of bottoming/recovery starting in 2020 for DRAM, NAND
Bernstein analyst Mark Newman says that though Memory industry profits remain challenged following downturns in both DRAM and NAND, he sees signs of bottoming and recovery starting in 2020 for both DRAM and NAND. His Top picks are SK Hynix and Micron (MU) followed by Samsung (SSNLF), all rated Outperform.
08/07/19
LEHM
08/07/19
INITIATION
LEHM
Equal Weight
Samsung initiated with an Equal Weight at Barclays
Barclays analyst Tim Long initiated Samsung with an Equal Weight rating and a price target of KRW 43,000. The analyst believes that while Samsung remains a technology powerhouse, they will see pressure in handsets, and will be forced to increase research and development spending, along with capex, to try to catch industry leaders.
TFX Teleflex
$322.10

-8.28 (-2.51%)

06/20/19
RAJA
06/20/19
NO CHANGE
RAJA
Teleflex voluntary recall manageable, says Raymond James
Raymond James analyst Lawrence Keusch maintained a Strong Buy rating and $350 price target on Teleflex after the company announced a "manageable" voluntary recall For one of its endotracheal tubes. Keusch noted that there is no revenue impact, and an immaterial $1M pretax profit & loss impact from the cost of recalling the product and discarding the inventory.
08/05/19
JMPS
08/05/19
NO CHANGE
Target $395
JMPS
Outperform
Teleflex price target raised to $395 from $325 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Teleflex to $395 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was "particularly impressive" as organic growth accelerated from Q1 into a double-digit range. The analyst believes that the stock should continue to appreciate given the management's efforts to boost profitability through "restructuring initiatives and manufacturing excellence programs."
08/02/19
NEED
08/02/19
NO CHANGE
Target $403
NEED
Buy
Teleflex price target raised to $403 from $325 at Needham
Needham analyst Mike Matson raised his price target on Teleflex to $403 and kept his Buy rating, saying its Q2 earnings beat shows the company caught "lightning in a bottle" with its UroLift system. The analyst points to the 9.6% organic revenue growth in the quarter in spite of the tougher comps and sees the 80bps decline in operating margins driven by the "incremental selling expense investments". Matson contends that the core business of TeleFlex is durable, and its Manta, and Percuvance could be sources of potential upside heading into 2020.
08/05/19
JMPS
08/05/19
NO CHANGE
Target $395
JMPS
Outperform
Teleflex price target raised to $395 from $325 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Teleflex to $395 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was "particularly impressive" as organic growth accelerated from Q1 into a double-digit range. The analyst believes that the stock should continue to appreciate given the management's efforts to boost profitability through "restructuring initiatives and manufacturing excellence programs."
WTKWY Wolters Kluwer
$0.00

(0.00%)

05/17/19
JPMS
05/17/19
DOWNGRADE
JPMS
Underweight
Wolters Kluwer downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Daniel Kerven downgraded Wolters Kluwer to Underweight from Neutral with a price target of 57 euros.

TODAY'S FREE FLY STORIES

20:20
11/21/19
11/21
20:20
11/21/19
20:20
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$66.17

-1.55 (-2.29%)

20:08
11/21/19
11/21
20:08
11/21/19
20:08
Periodicals
Live Nation 'looking forward' to taking part in Congress review of ticket market 

Report from Bloomberg.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRH

DiamondRock

$9.86

-0.085 (-0.86%)

19:53
11/21/19
11/21
19:53
11/21/19
19:53
Upgrade
DiamondRock rating change at Wells Fargo »

DiamondRock upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OOMA

Ooma

$11.18

-0.01 (-0.09%)

, IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

19:18
11/21/19
11/21
19:18
11/21/19
19:18
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$11.18

-0.01 (-0.09%)

IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

JWN

Nordstrom

$34.29

0.35 (1.03%)

SCVL

Shoe Carnival

$37.18

1.36 (3.80%)

SPLK

Splunk

$126.80

-0.04 (-0.03%)

GPS

Gap

$16.22

-0.05 (-0.31%)

ROST

Ross Stores

$111.81

1.39 (1.26%)

PSTG

Pure Storage

$19.84

-0.22 (-1.10%)

WSM

Williams-Sonoma

$68.76

0.195 (0.28%)

PNNT

PennantPark

$5.95

0.01 (0.17%)

ENTA

Enanta

$63.27

1.55 (2.51%)

INTU

Intuit

$270.01

-3.38 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 10

    Mar

  • 11

    Mar

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:08
11/21/19
11/21
19:08
11/21/19
19:08
Earnings
AES backs FY19 adjusted EPS view $1.30-$1.38, consensus $1.33 »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

WM

Waste Management

$111.23

-1.305 (-1.16%)

, RSG

Republic Services

$86.78

-0.91 (-1.04%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Initiation
Waste Management, Republic Services, Waste Connections, Clean Harbors, Stericycle, Casella Waste, Covanta initiated  »

Jefferies initiates…

WM

Waste Management

$111.23

-1.305 (-1.16%)

RSG

Republic Services

$86.78

-0.91 (-1.04%)

WCN

Waste Connections

$89.54

-0.28 (-0.31%)

CLH

Clean Harbors

$84.70

-0.75 (-0.88%)

SRCL

Stericycle

$62.49

0.76 (1.23%)

CWST

Casella Waste

$43.70

-0.39 (-0.88%)

CVA

Covanta

$14.43

-0.14 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Hot Stocks
AES Corp. says PUCO has modified DP&L rates »

The AES Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

, BTC

Bitcoin

$0.00

(0.00%)

19:02
11/21/19
11/21
19:02
11/21/19
19:02
Hot Stocks
ICE announces launch of Bakkt Bitcoin Cash Settled Monthly Futures contract »

Intercontinental Exchange…

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

18:51
11/21/19
11/21
18:51
11/21/19
18:51
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$58.01

-0.38 (-0.65%)

18:48
11/21/19
11/21
18:48
11/21/19
18:48
Initiation
Robert Half initiated at Jefferies »

Robert Half initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTZ

Hertz

$15.37

0.265 (1.76%)

18:46
11/21/19
11/21
18:46
11/21/19
18:46
Initiation
Hertz initiated at Jefferies »

Hertz initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$28.71

0.16 (0.56%)

18:44
11/21/19
11/21
18:44
11/21/19
18:44
Initiation
Avis Budget initiated at Jefferies »

Avis Budget initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$39.52

-1.45 (-3.54%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Hot Stocks
AMD CEO: The key for us is product generation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CTAS

Cintas

$253.61

-5.78 (-2.23%)

, BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Initiation
Cintas, Bright Horizons, Aramark, H&R Block, BrightView, Rollins, ServiceMaster initiated at Jefferies »

Jefferies initiates…

CTAS

Cintas

$253.61

-5.78 (-2.23%)

BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

ARMK

Aramark

$42.42

-1.37 (-3.13%)

HRB

H&R Block

$24.34

-0.15 (-0.61%)

BV

BrightView

$16.79

-2.525 (-13.08%)

ROL

Rollins

$35.77

-0.8 (-2.19%)

SERV

ServiceMaster

$36.16

-0.42 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

PINE

Alpine Income Properties

$0.00

(0.00%)

18:34
11/21/19
11/21
18:34
11/21/19
18:34
Syndicate
Alpine Income Properties 7.5M share IPO priced at $19.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

OTTW

Ottawa Bancorp

$13.39

-0.39 (-2.83%)

18:28
11/21/19
11/21
18:28
11/21/19
18:28
Hot Stocks
Ottawa Bancorp approves stock buyback of 317,307 shares »

Ottawa Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

18:27
11/21/19
11/21
18:27
11/21/19
18:27
Periodicals
Microsoft says granted U.S. license to do business with Huawei, Bloomberg says »

Microsoft said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

SITC

Site Centers

$14.28

-0.275 (-1.89%)

18:24
11/21/19
11/21
18:24
11/21/19
18:24
Upgrade
Site Centers rating change at Stifel »

Site Centers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Airlines

$90.96

-0.72 (-0.79%)

, BA

Boeing

$366.47

-4.275 (-1.15%)

18:23
11/21/19
11/21
18:23
11/21/19
18:23
Hot Stocks
United Airlines CEO: We don't think we are near a recession »

In an interview on…

UAL

United Airlines

$90.96

-0.72 (-0.79%)

BA

Boeing

$366.47

-4.275 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FAST

Fastenal

$35.15

-0.1 (-0.28%)

, GWW

Grainger

$312.66

0.305 (0.10%)

18:20
11/21/19
11/21
18:20
11/21/19
18:20
Initiation
Fastenal, Grainger, HD Supply, MSC Industrial, Wesco initiated at Jefferies »

Jefferies initiates…

FAST

Fastenal

$35.15

-0.1 (-0.28%)

GWW

Grainger

$312.66

0.305 (0.10%)

HDS

HD Supply

$39.10

-0.21 (-0.53%)

MSM

MSC Industrial

$73.66

-0.125 (-0.17%)

WCC

Wesco

$53.09

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 30

    Jan

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

, INFO

IHS Markit

$71.62

-0.38 (-0.53%)

18:06
11/21/19
11/21
18:06
11/21/19
18:06
Initiation
S&P Global, IHS Markit, Verisk Analytics, Gartner, FactSet, Equifax, TransUnion, CoStar Group initiated at Jefferies »

Jefferies initiates…

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

INFO

IHS Markit

$71.62

-0.38 (-0.53%)

VRSK

Verisk Analytics

$144.45

0.12 (0.08%)

IT

Gartner

$158.00

0.06 (0.04%)

FDS

FactSet

$258.20

-3.65 (-1.39%)

EFX

Equifax

$137.97

-1.15 (-0.83%)

TRU

TransUnion

$84.90

-1.34 (-1.55%)

CSGP

CoStar Group

$587.66

-7.45 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 19

    Dec

  • 19

    Dec

  • 07

    Jan

GPS

Gap

$16.22

-0.05 (-0.31%)

17:59
11/21/19
11/21
17:59
11/21/19
17:59
Periodicals
Gap to pull Old Navy brand from China in early 2020, Reuters reports »

Gap said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LB

L Brands

$17.18

1.78 (11.56%)

17:50
11/21/19
11/21
17:50
11/21/19
17:50
Hot Stocks
L Brands cancels Victoria's Secret Fashion Show for 'more current platforms' »

The CFO of L Brands,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

  • 27

    Feb

WCC

Wesco

$53.09

-0.02 (-0.04%)

17:47
11/21/19
11/21
17:47
11/21/19
17:47
Initiation
Wesco initiated at Jefferies »

Wesco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

17:47
11/21/19
11/21
17:47
11/21/19
17:47
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.